NYSEARCA:XLV
Health Care Select Sector SPDR Fund (XLV)
Financials 
Technical Analysis 
Sep 8, 2026, 12:00 amThis summary was created by AI, based on 5 opinions in the last 12 months.
The Health Care Select Sector SPDR Fund (XLV-N) is currently garnering positive attention from various experts due to its performance and growth potential within the healthcare sector. Reviews highlight a rotation away from tech stocks toward healthcare, fostering a stable investment environment. Notably, XLV has outperformed the S&P, boasting a 12% return compared to 3.6% over the past three months and a remarkable 26.8% return over the past year. Analysts express optimism surrounding innovative pharmaceuticals and advancements in AI, indicating that XLV could benefit from these trends. Experts recommend a cautious approach with a stop-loss strategy, while acknowledging a reasonable dividend yield, positioning XLV as an attractive option for investors seeking stability and growth in the current market landscape.
She's been holding onto this since it was flat, but now it's rising which is sticking because there's optimism in tech and healthcare. This rotation into HC has been stable and durable. HS will be one of the next big beneficiaries of AI, but the cost of AI has to fall first. It will take a little while, but you are paid to wait. Enter HC now.
;fill-opacity:1;'/%3e%3cpath%20d='M31%2018.6001V30H8V18.6001L14.1334%2022.4334L19.4999%2014L24.8669%2022.4334L31%2018.6001Z'%20fill='%23EE5432'%20style='fill:%23EE5432;fill:color(display-p3%200.9340%200.3310%200.1956);fill-opacity:1;'/%3e%3c/svg%3e){kind=small}
Premium contentThis is another U.S. ETF that's benefiting from the current rotation out of AI. XLV has outperformed the S&P 12% vs. 3.6% in the past three months and has returned 26.8% in the past year. Healthcare is a safe, steady play at a 0.51 beta. XLV pays only a 1.6% dividend costs but costs only eight basis points.
Healthcare is not a value trap. It's the worst performing sector this year--and could get worse--but the knife has fallen. If you're looking for something to buy in a market with high valuations and possible headlines from inflation prints, look at healthcare. Healthcare is insulated from interest rate volatility. If you're worried about Trump's attitude to phama, then look at healthcare equipment and services and buy IHI.
He's overweight healthcare and within that is overweight biotech and pharma. There's a reversion to the mean after a brutal election year, but that's always the case. Relief comes when presidential policies are not as dire as expected. These stock have tremendous valuations and pay good dividends and there's growth with aging demographics.
Jim Lebenthal
A basket of names, with some winners and some losers. LLY is the top holding, that's a winner. Also holds JNJ and PFE, which haven't done particularly well.
He owns NVO, MCK and CAH. He likes those companies where the only serious competition comes from 1 or 2 others, as they can control pricing power. Diabetes and weight loss are definite growth areas. See his Top Picks.
Excellent name that offers defensive protection. Strength in health care sector good for investors. Weakness in sector that past 1-2 years is creating buying opportunity.
Brooke ThackrayBought this to be defensive, however, health care wasn't that defensive this year. Now, HC is past seasonality and he doesn't like it.
Brooke Thackray'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
Popular Articles
Health Care Select Sector SPDR Fund (XLV) Frequently Asked Questions
What is Health Care Select Sector SPDR Fund stock symbol?
Health Care Select Sector SPDR Fund is a American stock, trading under the symbol XLV (previously XLV-N on Stockchase) on the NYSE Arca (XLV). It is usually referred to as AMEX:XLV or XLV
Is Health Care Select Sector SPDR Fund a buy or a sell?
In the last year, 4 stock analysts issued a Buy, Sell, or Hold rating on XLV (previously XLV-N on Stockchase). 4 analysts recommended to BUY and 0 analysts recommended to SELL the stock. The latest stock analyst rating is TOP PICK. Read the latest stock experts' ratings for Health Care Select Sector SPDR Fund.
Is Health Care Select Sector SPDR Fund a good investment or a top pick?
Health Care Select Sector SPDR Fund was recommended as a Top Pick by The Panic-Proof Portfolio (Stockchase Research) on 2026-08-20. Read the latest stock experts ratings for Health Care Select Sector SPDR Fund.
Why is Health Care Select Sector SPDR Fund stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for Health Care Select Sector SPDR Fund.
Is Health Care Select Sector SPDR Fund worth watching?
Health Care Select Sector SPDR Fund is followed by 90 investors on Stockchase and is a trending stock that is worth watching.
What is Health Care Select Sector SPDR Fund stock price?
On 2026-09-08, Health Care Select Sector SPDR Fund (XLV) stock closed at a price of $167.13.
'%20fill='%23FFB800'%3e%3cg%20id='filled-.-button'%20transform='translate(120.000000,%20413.999972)'%3e%3cpath%20d='M101.499729,2.82302245e-05%20C102.285413,-0.00432461793%20103.254164,0.496634241%20103.645655,1.25173399%20L103.712109,1.39623206%20L105.747863,6.45331817%20L111.028779,6.80428588%20C111.60867,6.84282525%20112.147242,7.1236355%20112.517275,7.58038413%20C113.223405,8.45199453%20113.142035,9.72214747%20112.357105,10.4940033%20L112.234099,10.6059323%20L108.072656,14.10894%20L109.356339,19.592529%20C109.472157,20.0872738%20109.394126,20.6085551%20109.13883,21.0455786%20C108.624329,21.9263208%20107.536956,22.2447485%20106.649713,21.8010736%20L106.511398,21.7246573%20L101.5,18.7715858%20L96.4886024,21.7246573%20C95.5790916,22.2767096%2094.4027498,21.9726757%2093.8611695,21.0455786%20C93.6058745,20.6085551%2093.5278433,20.0872738%2093.6436608,19.592529%20L94.9273443,14.10894%20L90.7659013,10.6059323%20C89.8680707,9.85015912%2089.7412886,8.49557505%2090.4827254,7.58038413%20C90.8527577,7.1236355%2091.39133,6.84282525%2091.9712215,6.80428588%20L97.2521374,6.45331817%20L99.2878908,1.39623206%20C99.6240254,0.561228427%20100.665516,-0.00460395016%20101.499729,2.82302245e-05%20Z'%20id='top-picks-.-icon-copy-7'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e){kind=small}
Excitement around MRNA and MRK combined drugs to likely protect patients from melanoma recurrence could provide a home in this sector for investors looking to rotate away from tech. This low-MER ETF hold numerous pharma and health-care companies. We recommend setting a stop-loss at $161, looking to achieve $204 -- upside potential of 18%. Yield 1.4%